Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK
{{output}}
Background: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. ... ...
